NASDAQ •
Healthcare •
Biotechnology •
Quote as of 07/27/2026 11:33
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization8,083.01 mln
Float78.74 mln
Earnings Date08/06/2026
Piotroski F-Score
2
/ 9
Weak
1-Year Forecast
47.19
Attractive
Relative Strength
87
/ 100
Strongly outperforming
Debt / Equity
0.00
Debt-free
ROE
-68.80
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Immunovant is a New York-based medical research company focused on developing new treatments for autoimmune conditions, where the immune system mistakenly attacks the body. The company is working on two experimental drugs targeting a range of serious diseases, including rheumatoid arthritis, lupus, and several rare neurological and eye conditions. Founded in 2018, Immunovant operates as part of Roivant Sciences.
